ConductScience.org, home

Paper23190886

The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.

Zhou H and 13 others. J Invest Dermatol, 2013. Cited by 47 papers, by iCite.

Cite this record

ConductScience Library. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. Papers, record 23190886. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23190886

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
PubMed
Journal
J Invest Dermatol
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
47
iCite
Relative citation ratio, by iCite
1.37
iCite
Revised in PubMed
2022-03-09
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou HHong
2Ekmekcioglu SSuhendan
3Marks JWJohn W
4Mohamedali KAKhalid A
5Asrani KKaushal
6Phillips KKKeeley K
7Brown SASharron A N
8Cheng EEmily
9Weiss MBMichele B
10Hittelman WNWalter N
11Tran NLNhan L
12Yagita HHideo
13Winkles JAJeffrey A
14Rosenblum MGMichael G

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunologic FactorsMajor topic
ImmunotoxinsMajor topic
MelanomaMajor topic
Receptors, Tumor Necrosis FactorMajor topic
Skin NeoplasmsMajor topic
Animals
Cell Death
Cell Line, Tumor
Drug Design
Female
Humans
Mice
Mice, Inbred BALB C
NF-kappa B
Protein Binding
Signal Transduction
TWEAK Receptor
Up-Regulation
Xenograft Model Antitumor Assays

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016672NCI NIH HHSUnited StatesP01CA016672PubMed and NIHNIH RePORTER
R01 CA130940NCI NIH HHSUnited StatesR01CA130940PubMed and NIHNIH RePORTER
T32 HL007698NHLBI NIH HHSUnited StatesT32HL007698PubMed and NIHNIH RePORTER
CA16672NCI NIH HHSUnited StatesP01CA016672PubMed and NIHNIH RePORTER
CA125103NCI NIH HHSUnited StatesR01CA125103PubMed and NIHNIH RePORTER
R01 NS055126NINDS NIH HHSUnited StatesR01NS055126PubMed and NIHNIH RePORTER
R01 CA125103NCI NIH HHSUnited StatesR01CA125103PubMed and NIHNIH RePORTER
P30CA016672NIHNIH RePORTER

Download CSV of grants

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112651623The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors.Am J Pathol2003https://conductscience.org/library/papers/12651623PubMed
221697654Development of an Fn14 agonistic antibody as an anti-tumor agent.MAbs2011https://conductscience.org/library/papers/21697654PubMed
321629286Ipilimumab.Nat Rev Drug Discov2011https://conductscience.org/library/papers/21629286PubMed
420482674Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.J Cutan Pathol2010https://conductscience.org/library/papers/20482674PubMed
514713109SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.Clin Exp Metastasis2003https://conductscience.org/library/papers/14713109PubMed
616015365Caspase-independent cell death.Nat Med2005https://conductscience.org/library/papers/16015365PubMed
719513634Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway.Results Probl Cell Differ2009https://conductscience.org/library/papers/19513634PubMed
822037033Vemurafenib.Nat Rev Drug Discov2011https://conductscience.org/library/papers/22037033PubMed
919917835Final version of 2009 AJCC melanoma staging and classification.J Clin Oncol2009https://conductscience.org/library/papers/19917835PubMed
1011393586Microtiter-based assay for evaluating the biological activity of ribosome-inactivating proteins.Pharmacol Toxicol2001https://conductscience.org/library/papers/11393586PubMed
1112629507Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.Oncogene2003https://conductscience.org/library/papers/12629507PubMed
1215342808Management of cutaneous melanoma.N Engl J Med2004https://conductscience.org/library/papers/15342808PubMed
1317594693Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma.Int J Cancer2007https://conductscience.org/library/papers/17594693PubMed
1412496418Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.J Immunol2003https://conductscience.org/library/papers/12496418PubMed
1518927540Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside.J Invest Dermatol2008https://conductscience.org/library/papers/18927540PubMed
1621828059Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.Carcinogenesis2011https://conductscience.org/library/papers/21828059PubMed
1717981048TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease.Cytokine2007https://conductscience.org/library/papers/17981048PubMed
1819944700Stability and DNA-binding ability of the bZIP dimers formed by the ATF-2 and c-Jun transcription factors.J Mol Biol2010https://conductscience.org/library/papers/19944700PubMed
1920406483Melanoma: a model for testing new agents in combination therapies.J Transl Med2010https://conductscience.org/library/papers/20406483PubMed
2012789290Apoptosis and melanoma chemoresistance.Oncogene2003https://conductscience.org/library/papers/12789290PubMed

See all 37 referencesDownload CSV of references

Cited by40

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.

PMIDTitleJournalYearIn PapersSource
40585358The TWEAK/Fn14 signaling mediates skeletal muscle wasting during cancer cachexia.iScience2025https://conductscience.org/library/papers/40585358PubMed
40444089Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment.Front Oncol2025https://conductscience.org/library/papers/40444089PubMed
38404743Deciphering the Synthetic and Refolding Strategy of a Cysteine-Rich Domain in the Tumor Necrosis Factor Receptor (TNF-R) for Racemic Crystallography Analysis and d-Peptide Ligand Discovery.ACS Bio Med Chem Au2024https://conductscience.org/library/papers/38404743PubMed
37812740Impact of Targeting Moiety Type and Protein Corona Formation on the Uptake of Fn14-Targeted Nanoparticles by Cancer Cells.ACS Nano2023https://conductscience.org/library/papers/37812740PubMed
36678596Momordica cochinchinensis (Gấc) Seed Extracts Induce Apoptosis and Necrosis in Melanoma Cells.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/36678596PubMed
36339601Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy.Front Pharmacol2022https://conductscience.org/library/papers/36339601PubMed
36069059Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity.EMBO Mol Med2022https://conductscience.org/library/papers/36069059PubMed
36061481Methotrexate Mechanism of Action in Plaque Psoriasis: Something New in the Old View.J Clin Aesthet Dermatol2022https://conductscience.org/library/papers/36061481PubMed
35707713Lower Expression of TWEAK is Associated with Poor Survival and Dysregulate TIICs in Lung Adenocarcinoma.Dis Markers2022https://conductscience.org/library/papers/35707713PubMed
34917619Identification of Pan-Cancer Biomarkers Based on the Gene Expression Profiles of Cancer Cell Lines.Front Cell Dev Biol2021https://conductscience.org/library/papers/34917619PubMed
33937046A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma.Front Oncol2021https://conductscience.org/library/papers/33937046PubMed
32958685Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.J Immunother Cancer2020https://conductscience.org/library/papers/32958685PubMed
31998833Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer.Sci Adv2020https://conductscience.org/library/papers/31998833PubMed
30218067Autophagy differentially regulates TNF receptor Fn14 by distinct mammalian Atg8 proteins.Nat Commun2018https://conductscience.org/library/papers/30218067PubMed
29681850Tnfrsf12a-Mediated Atherosclerosis Signaling and Inflammatory Response as a Common Protection Mechanism of Shuxuening Injection Against Both Myocardial and Cerebral Ischemia-Reperfusion Injuries.Front Pharmacol2018https://conductscience.org/library/papers/29681850PubMed
29076988The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations.Toxins (Basel)2017https://conductscience.org/library/papers/29076988PubMed
29075649Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells.J Immunol Res2017https://conductscience.org/library/papers/29075649PubMed
29054986Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.Mol Cancer Ther2018https://conductscience.org/library/papers/29054986PubMed
28138696Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration in vitro.Mol Med Rep2017https://conductscience.org/library/papers/28138696PubMed
28103571Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.Oncotarget2017https://conductscience.org/library/papers/28103571PubMed

See all 40 cited byDownload CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23190886

GET https://conductscience.org/api/papers/v1/23190886/references?page=2